Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7917084> ?p ?o }
Showing triples 1 to 72 of
72
with 100 triples per page.
- Q7917084 subject Q8252271.
- Q7917084 subject Q8431759.
- Q7917084 subject Q8878163.
- Q7917084 abstract "Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.Vatalanib is being developed by Bayer Schering and Novartis. It inhibits all known VEGF receptors, as well as platelet-derived growth factor receptor-beta and c-kit, but is most selective for VEGFR-2.".
- Q7917084 atcPrefix "none".
- Q7917084 casNumber "212141-54-3".
- Q7917084 chEBI "90620".
- Q7917084 drugbank "DB04879".
- Q7917084 fdaUniiCode "5DX9U76296".
- Q7917084 iupacName "N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin- 1-amine".
- Q7917084 pubchem "151194".
- Q7917084 thumbnail Vatalanib.svg?width=300.
- Q7917084 wikiPageExternalLink results?intr=%22Vatalanib%22.
- Q7917084 wikiPageWikiLink Q10916362.
- Q7917084 wikiPageWikiLink Q117636.
- Q7917084 wikiPageWikiLink Q12078.
- Q7917084 wikiPageWikiLink Q127076.
- Q7917084 wikiPageWikiLink Q1340863.
- Q7917084 wikiPageWikiLink Q1418791.
- Q7917084 wikiPageWikiLink Q1436668.
- Q7917084 wikiPageWikiLink Q14864419.
- Q7917084 wikiPageWikiLink Q179661.
- Q7917084 wikiPageWikiLink Q18028241.
- Q7917084 wikiPageWikiLink Q181876.
- Q7917084 wikiPageWikiLink Q186889.
- Q7917084 wikiPageWikiLink Q188874.
- Q7917084 wikiPageWikiLink Q1988322.
- Q7917084 wikiPageWikiLink Q20969938.
- Q7917084 wikiPageWikiLink Q2112244.
- Q7917084 wikiPageWikiLink Q30612.
- Q7917084 wikiPageWikiLink Q390551.
- Q7917084 wikiPageWikiLink Q40878.
- Q7917084 wikiPageWikiLink Q409464.
- Q7917084 wikiPageWikiLink Q412197.
- Q7917084 wikiPageWikiLink Q41861.
- Q7917084 wikiPageWikiLink Q425265.
- Q7917084 wikiPageWikiLink Q4356503.
- Q7917084 wikiPageWikiLink Q45959.
- Q7917084 wikiPageWikiLink Q507154.
- Q7917084 wikiPageWikiLink Q5090632.
- Q7917084 wikiPageWikiLink Q539568.
- Q7917084 wikiPageWikiLink Q545590.
- Q7917084 wikiPageWikiLink Q574834.
- Q7917084 wikiPageWikiLink Q626251.
- Q7917084 wikiPageWikiLink Q6594591.
- Q7917084 wikiPageWikiLink Q7202242.
- Q7917084 wikiPageWikiLink Q7251487.
- Q7917084 wikiPageWikiLink Q8047.
- Q7917084 wikiPageWikiLink Q824258.
- Q7917084 wikiPageWikiLink Q8252271.
- Q7917084 wikiPageWikiLink Q8431759.
- Q7917084 wikiPageWikiLink Q8878163.
- Q7917084 wikiPageWikiLink Q9368.
- Q7917084 wikiPageWikiLink Q9377.
- Q7917084 wikiPageWikiLink Q9690.
- Q7917084 wikiPageWikiLink Q974135.
- Q7917084 atcPrefix "none".
- Q7917084 casNumber "212141".
- Q7917084 chebi "90620".
- Q7917084 drugbank "DB04879".
- Q7917084 iupacName "N--4-phthalazin- 1-amine".
- Q7917084 pubchem "151194".
- Q7917084 unii "5".
- Q7917084 type ChemicalSubstance.
- Q7917084 type Drug.
- Q7917084 type ChemicalObject.
- Q7917084 type Thing.
- Q7917084 type Q8386.
- Q7917084 comment "Vatalanib (INN, codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer, particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active, that is, it is effective when taken by mouth.Vatalanib is being developed by Bayer Schering and Novartis.".
- Q7917084 label "Vatalanib".
- Q7917084 differentFrom Q7914515.
- Q7917084 depiction Vatalanib.svg.